Idarucizumab - Boehringer Ingelheim
At a glance
- Drug Originator Boehringer Ingelheim
- Drug Class Antidotes; Coagulants; Fab fragments; Monoclonal antibodies
- Mechanism of Action Immunomodulators
- USA Patent Applicants BOEHRINGER INGELHEIM
- USA Patents 6
- BLAs 1
- International Patents 45
Disclaimer